针对回购股份的目的，药明康德表示，为维护公司价值和股东权益，增强投资者信心，综合考虑公司财务状况、未来发展及合理估值水平等因素，公司拟使 用自有资金和/或自筹资金进行股份回购，以推进公司股票市场价格与内在价值相匹配。 4月9日，药明康德（603259）再度抛出大额回购计划，拟以10亿元回购公司股份并全部予以注销，这已是药明康德年内第二次计划回购。不止药明康德，仅 在4月8日至9日，就有多只医药股发布回购相关的公告，包括新和成、复星医药等。 先看药明康德。4月9日，药明康德发布公告称，为积极维护公司价值及股东权益，公司于4月8日召开第三届董事会第二十次会议审议通过了《关于2025年第 二次以集中竞价交易方式回购公司A股股份的议案》，同意以维护公司价值及股东权益为目的，通过集中竞价方式回购公司A股股份并全部予以注销的回购 方案。本次回购资金总额为10亿元，回购股份资金来源为公司自有资金和/或自筹资金，本次回购股份价格不超过97.24元/股（含）。 值得一提的是，药明康德曾于3月18日披露《关于2025年以集中竞价交易方式回购A股股份的预案》，同样拟以10亿元回购公司股份并予以注销。这也意味 着，2025年以来，药 ...

Core Views - The report maintains a positive outlook on the biopharmaceutical industry, expecting it to outperform the market due to minimal impact from recent U.S. tariff policies on drug sectors [4][5] - The report emphasizes continued optimism for innovative drugs and sectors related to consumer recovery, highlighting the resilience of the pharmaceutical sector amidst tariff changes [4][5] Industry Insights - The recent U.S. tariff policy has a limited effect on the pharmaceutical sector, with most drugs, including various chemical drugs, vaccines, and biological products, exempt from tariffs. Raw materials like vitamins and amino acids are also on the exemption list [4][27] - The report suggests that the innovative drug sector has shown significant growth, providing a selection of quality stocks based on criteria such as strong fundamentals, potential in research pipelines, and favorable cash positions [4][5] Investment Strategy - The report recommends focusing on four main themes: "Innovation," "Going Global," "Equipment Upgrades," and "Consumer Recovery" [5] - **Innovation**: Invest in globally competitive innovative drugs and promising categories, with specific companies highlighted such as BeiGene and East China Pharmaceutical [5] - **Going Global**: Identify opportunities in overseas markets, with companies like Mindray Medical and Sinocare suggested for investment [5] - **Equipment Upgrades**: Expect support for medical equipment updates from government policies, with companies like Mindray Medical and United Imaging Healthcare recommended [5] - **Consumer Recovery**: Anticipate a rebound in sectors like ophthalmology and aesthetic medicine, with companies like Prue Eye Hospital and Tongce Medical highlighted [5] Key Companies to Watch - **Nocare Biopharma**: Expected to achieve revenue of 1.009 billion in 2024, with a 49% year-on-year growth in sales of its core product, Oubatinib [6] - **Sihuan Pharmaceutical**: Strong fundamentals with a stable performance, and a promising pipeline with multiple products expected to be approved between 2025 and 2027 [9] - **East China Pharmaceutical**: Anticipated growth driven by the commercialization of domestic nuclear medicine products and a robust R&D pipeline [10] - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products, indicating potential for accelerated profit growth [11] - **Aier Eye Hospital**: Benefiting from growing demand in ophthalmology and favorable policies for private specialty hospitals, with significant expansion plans [21]

Market Overview - After the Spring Festival and during the Two Sessions, the TMT sector led by Deepseek has initiated a "revaluation of Chinese assets" trend, supported by a relatively stable RMB exchange rate and positive policy expectations[1] - The A-share and Hong Kong technology sectors currently exhibit a high risk appetite, although adjustments have been observed since mid-March due to uncertainties surrounding the new round of "reciprocal tariffs" from the US and concerns over AI "computing power bubbles"[1] - In March, the Shanghai Composite Index, CSI 300 Index, and ChiNext Index recorded gains of +0.45%, -0.07%, and -3.07%, respectively[1] Policy and Economic Outlook - The 2025 Two Sessions emphasized expanding domestic demand and promoting consumption as primary objectives, with a focus on addressing low domestic inflation and external uncertainties[2] - The "Consumption Promotion Action Plan" issued on March 16 aims to enhance consumer capacity and stabilize the stock market, with expectations for new capital market policies to accelerate implementation[2] - The central bank reiterated the need for a moderately loose monetary policy, with potential for reserve requirement ratio (RRR) and interest rate cuts based on economic conditions[2] Investment Recommendations - Focus on large consumption and cyclical industries in Q2, particularly those showing signs of recovery or strong performance[3] - Continue to monitor defensive sectors such as banking and dividend stocks due to external uncertainties[4] - The long-term trend for AI remains positive, with significant investment from major domestic companies, presenting potential short-term investment opportunities during market corrections[5] Selected Stock Portfolio - The recommended portfolio includes stocks from various sectors: China Mobile, Hongri Da, Lu Wei Optoelectronics, Sinovac Biotech, and others, covering telecommunications, pharmaceuticals, machinery, and non-bank financials[5]

Group 1 - The animal vaccine concept increased by 2.08%, ranking 8th among concept sectors, with 16 stocks rising, including *ST Xianfeng which hit the daily limit, and Yongshun Biological, Zhongmu Co., and Weilan Biological showing gains of 8.39%, 4.84%, and 4.03% respectively [1] - The animal vaccine sector attracted a net inflow of 0.74 billion yuan, with 10 stocks receiving significant capital inflow, led by Kanghua Biological with a net inflow of 37.30 million yuan, followed by Zhongmu Co. and Ruipu Biological with 31.65 million yuan and 12.25 million yuan respectively [2][3] - The top stocks by net inflow ratio included *ST Xianfeng at 87.36%, Kanghua Biological at 11.65%, and Zhongmu Co. at 9.97% [3] Group 2 - The animal vaccine sector's performance was part of a broader market trend, with other sectors like poultry and industrial mother machines also showing positive gains of 3.73% and 3.13% respectively, while sectors like combustible ice and epoxy propylene experienced declines [2] - The trading volume and turnover rates for leading stocks in the animal vaccine sector indicate active trading, with Kanghua Biological having a turnover rate of 4.17% and Zhongmu Co. at 4.51% [3][4] - Stocks such as Kexing Pharmaceutical and Guoyao Modern saw declines of 2.67% and 0.61% respectively, highlighting a mixed performance within the broader pharmaceutical sector [1][4]

Core Insights - The article discusses the rising valuation of companies involved in the development of weight loss drugs, particularly focusing on the GLP-1 receptor agonist, Semaglutide, which has gained popularity for its weight loss effects and is part of a national initiative for weight management in China [1][2][6]. Company Insights - Zhifei Biological Products has plans to acquire Chuan'an Biotechnology, which is positioned to benefit from the growing market for Semaglutide and related drugs [7][8]. - Chuan'an Biotechnology is in the lead for the first batch of generic Semaglutide drugs, with several candidates in various stages of clinical trials, indicating a strong pipeline for future growth [7][8]. - Zhifei Biological's strategy emphasizes self-research and development, alongside partnerships and investments, to enhance its innovation capabilities and expand into the metabolic disease sector [8]. Industry Insights - The market for Semaglutide in China is projected to grow significantly, from 2.5 billion yuan in 2022 to 43.9 billion yuan by 2032, reflecting a compound annual growth rate (CAGR) of 33% [6]. - The obesity rate in China is expected to reach 65.3% by 2030, and the number of type 2 diabetes patients is projected to hit 140 million by 2032, creating a substantial market opportunity for weight loss and diabetes management drugs [6][7]. - The patent for Semaglutide in China will expire in 2026, allowing companies that can launch generics to capture significant market share [7].

Group 1: Company Performance - BYD reported a net profit of 40.254 billion yuan for 2024, representing a year-on-year increase of 34% [1] - The company's operating revenue reached 777.102 billion yuan, up 29.02% compared to the previous year [1] - Satellite Chemical achieved a net profit of 6.072 billion yuan in 2024, marking a 26.77% increase year-on-year [2] Group 2: Dividend Proposals - BYD plans to distribute a cash dividend of 39.74 yuan per 10 shares (tax included) [1] - Satellite Chemical intends to distribute a cash dividend of 5 yuan per 10 shares (tax included) [2] Group 3: Stock Market Activity - Junshen Co. is in the preparatory stage for an overseas transshipment project, which has not yet commenced operations [2] - Zhenhua Heavy Industry's stock price increased by 33.58% over a short period, despite no significant changes in its fundamentals [3] - Yuxing Anchor Chain's stock also experienced a significant price increase, with its main business remaining stable [4] Group 4: Strategic Moves - Taihao Technology plans to acquire a 13.87% stake in Jiangxi Taihao Military Group through a share issuance [7] - Dafeng Industrial signed a strategic cooperation agreement with Shanghai Zhiyuan New Technology Co., aiming to explore innovative applications in entertainment and sports [8]

科兴制药: 关于以集中竞价交易方式回购股份的回 购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不超过人民币 6,000 万元（含），不低于人民币 3,000 万元（含）。 ● 回购股份资金来源：自有资金和股票回购专项贷款资金，其中专项贷款金额不 超过 4,950 万元。 ● 回购股份用途：股权激励或员工持股计划。 ● 回购股份价格：不超过人民币 29.77 元/股（含）， 该价格不高于公司董事会通 过回购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：通过上海证券交易所交易系统以集中竞价交易方式。 证券代码：688136 证券简称：科兴制药 公告编号：2025-009 科兴生物制药股份有限公司 ● 回购股份期限：自公司董事会审议通过本次回购股份方案之日起 12 个月内。 ● 相关股东是否存在减持计划：截至回购预案披露日，公司董事、监事、高级管 理人员、控股股东、实际控制人、回购股份提议人、持股 5%以上的股东在未来 3 个月、未来 6 个月内暂不存在减持 ...

从行业分布来看，电子行业个股在调研热度前十榜单中占据重要地位。盛美上海、汇顶科技和深南电路 分别以25次、24次和19次的调研次数位列前十。 上周公募调研超百家公司，德赛西威最受关注 转自：新华财经 新华财经上海3月24日电 公募基金的调研维持活跃态势。据公募排排网最新统计数据，上周（2025年3 月17日至23日）有136家公募机构对103只A股个股展开调研，覆盖24个申万一级行业，合计调研次数达 668次。 在103只被调研个股中，有40只个股被调研频次不低于5次，相当于每个交易日至少接受一次公募机构调 研。具体来看，21只个股获得5至9次调研，10只个股获得10至19次调研，6只个股获得20至29次调研， 另有3只个股被调研不少于30次。其中，计算机行业龙头德赛西威以43次调研位居榜首，成为最受公募 机构关注的个股。参与调研的机构阵容强大，包括华夏基金、天弘基金等43家知名公募机构。 从机构排名来看，嘉实基金以18次的调研次数位居榜首。该机构重点关注的个股中，浙江荣泰、江河集 团和塔牌集团表现突出，上周股价涨幅显著。博时基金以16次的调研次数紧随其后，其调研组合中的科 兴制药、东方精工和塔牌集团同样录得 ...

上周公募调研超百家公司 德赛西威最受关注 新华财经上海3月24日电公募基金的调研维持活跃态势。据公募排排网最新统计数据，上周（2025 年3月17日至23日）有136家公募机构对103只A股个股展开调研，覆盖24个申万一级行业，合计调研次 数达668次。 在103只被调研个股中，有40只个股被调研频次不低于5次，相当于每个交易日至少接受一次公募机 构调研。具体来看，21只个股获得5至9次调研，10只个股获得10至19次调研，6只个股获得20至29次调 研，另有3只个股被调研不少于30次。其中，计算机行业龙头德赛西威以43次调研位居榜首，成为最受 公募机构关注的个股。参与调研的机构阵容强大，包括华夏基金、天弘基金等43家知名公募机构。 从行业分布来看，电子行业个股在调研热度前十榜单中占据重要地位。盛美上海、汇顶科技和深南 电路分别以25次、24次和19次的调研次数位列前十。 | 上周公募机构调研次数排名前十的▲股公司 | | | | | --- | --- | --- | --- | | 被调研 A 股公司简称 所属申万一级行业 周度股价涨跌幅 被调研次数(次) | | | | | 德塞西威 | 计算机 | - ...

Core Viewpoint - Institutional research enthusiasm remains high, with 137 listed companies disclosing research summaries, indicating ongoing interest in market dynamics and potential investment opportunities [2][3]. Group 1: Institutional Research Highlights - During the week of March 17 to March 21, only over 30% of companies surveyed by institutions achieved positive returns, with Tianhai Defense leading with a 25.23% increase [2]. - Tapa Group emerged as a key focus, receiving 6 institutional visits and engaging 154 institutions, highlighting its significance in the cement industry [3]. - Tapa Group aims to produce and sell over 16.3 million tons of cement by 2025, aligning its production goals with capacity control requirements [3]. Group 2: Company-Specific Insights - Shengmei Shanghai, a semiconductor cleaning equipment company, hosted 146 institutional visits, focusing on its growth in the sulfuric acid cleaning equipment market [5][6]. - Shengmei Shanghai is optimistic about its high-temperature sulfuric acid products and aims for better overseas market performance in 2024 [6]. - Chujian New Materials is expanding into high-end copper conductor materials and has attracted institutional interest due to its developments in robotics [7][9]. - Chujian New Materials has achieved breakthroughs in ultra-fine copper conductor technology, which is now ready for mass production [9].